Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2019-07-16 Capital/Financing Update
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
유동성공급계약의변경
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding a change in the liquidity provider (designated advisor) for the company's stock. It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a regulatory announcement regarding a corporate contract change that does not fall into the other specific categories, it is classified as a general regulatory filing.
2019-07-16 Korean
지정자문인선임계약의체결
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the appointment of a new designated advisor (유진투자증권) following the termination of a previous contract. It is a corporate announcement regarding a specific business arrangement that does not fit into financial reporting, M&A, or other specific categories, making it a general regulatory announcement.
2019-07-16 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for the company '에이비온' (Abion). It outlines the date, time, location, and the agenda items (such as articles of association changes, director appointments, and stock option grants). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2019-07-09 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Extraordinary General Meeting. It does not contain the full proxy materials or the meeting minutes themselves, but rather serves as a formal regulatory notice of a corporate action. Given it is a specific regulatory announcement that does not fit into the other categories like dividend or share issuance, it falls under the general regulatory filing category.
2019-07-09 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (Abion) regarding the 'Acquisition of shares and securities of another corporation' (타법인 주식 및 출자증권 취득결정). This is a standard corporate disclosure form used in the Korean market (DART system) to announce capital investments or M&A-related activities. Since it details the acquisition of a subsidiary for clinical research purposes, it falls under the category of M&A activity/corporate investment announcements.
2019-07-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used when a director or major shareholder reports changes in their personal shareholdings. This falls under the 'Director's Dealing' category, as it details personal share transactions by a company executive (Kim Ji-hoon).
2019-06-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.